Eyepoint Pharmaceuticals Stock News

For speculators that are seeking the next big upside opportunity, you may consider these oversold Nasdaq stocks to buy now. The post 7 Wildly Oversold Nasdaq Stocks to Buy Now appeared first on Invest

WATERTOWN, Mass., June 10, 2022 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the

WATERTOWN, Mass., May 17, 2022 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the lives

EyePoint Pharmaceuticals (EYPT) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising ear

EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT ) Q1 2022 Earnings Conference Call May 4, 2022 8:30 AM ET Company Participants George Elston - CFO Nancy Lurker - President and CEO Jay Duker - COO Scott Jo

EyePoint Pharmaceuticals Inc (NASDAQ: EYPT) executed a license agreement with Betta Pharmaceuticals Co Ltd to develop and commercialize EYP-1901 in Mainland China, Hong Kong, Macau, and Taiwan. 

EyePoint Pharmaceuticals Inc (NASDAQ: EYPT ) has secured senior secured credit facilities of $45 million from Silicon Valley Bank to replace its existing credit facility with CRG Servicing LLC . Under the terms of the new agreement, a $30 million term loan facility and an asset-based revolving credit … Full story available on Benzinga.com

EyePoint Pharmaceuticals (EYPT) entered into a loan agreement providing for senior secured credit facilities in the amount of $45M with Silicon Valley Bank to replace its existing…

EyePoint Pharmaceuticals, Inc. (EYPT) CEO Nancy Lurker on Q4 2021 Results - Earnings Call Transcript

DBV Technologies DBVT +16%. EyePoint Pharmaceuticals (EYPT) +14%. NuCana (NCNA) -54%. MediWound (MDWD) -15%.

EyePoint Pharmaceuticals press release (EYPT): Q4 GAAP EPS of -$0.59 misses by $0.03.Revenue of $11.54M (+61.9% Y/Y) beats by $1.75M.

– Positive EYP-1901 DAVIO Phase 1 eight-month data was presented at Angiogenesis, Exudation, and Degeneration 2022 virtual meeting on February 12, 2022, continuing positive safety and efficacy profile seen at six-month readout

EyePoint Pharmaceuticals (EYPT) delivered earnings and revenue surprises of -18% and 14.72%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the sto

Companies Reporting Before The Bell • Travelzoo (NASDAQ: TZOO ) is expected to report quarterly earnings at $0.13 per share on revenue of $18.23 million. • Urban One (NASDAQ: UONEK ) is likely to report earnings for its fourth quarter. • Tile Shop Holdings (NASDAQ: TTSH ) is likely to report earnings for its fourth quarter. • Oxford Square Capital (NASDAQ: OXSQ ) is estimated to report quarterly earnings at $0.09 per share on revenue of $10.30 million. • Aurora Mobile (NASDAQ: JG ) is projected to report quarterly loss at $0.07 per share on revenue of $15.65 million. • Mobile TeleSystems (NYSE: MBT ) is estimated to report quarterly earnings at $0.19 per share on revenue of $1.69 billion. • LENSAR (NASDAQ: LNSR ) is estimated to report quarterly loss at $0.52 per share on revenue of $8.70 million. • Bluegreen Vacations (NYSE: BVH ) is likely to report quarterly earnings at $0.62 per share on revenue of $203.89 million. • Fulcrum Therapeutics (NASDAQ: FULC ) is projected to report quarterly loss at $0.